Table 1 Baseline characteristics of the study population (n = 628)
|  | Men (n = 257) | Premenopausal women (n = 59) | Postmenopausal women (n = 312) | P value* |
|---|---|---|---|---|
Age, years | 57.6 ± 10.2§ | 47.3. ± 5.2 | 63.8 ± 8.5 | < 0.001 |
BMI, kg/m2 | 24.8 ± 3.0 | 25.2 ± 3.6 | 25.2 ± 3.2 | 0.935 |
Waist, cm | 85.9 ± 9.2§ | 72.9 ± 13.5 | 79.4 ± 9.0 | < 0.001 |
Smoking, n (%) | 88 (34.2%)§ | 4 (6.8%) | 18 (5.8%) | 0.765 |
Hypertension, n (%) | 130 (50.6%) | 13 (22.0%) | 151 (48.4%) | < 0.001 |
Diabetes, n (%) | 47 (18.3%) | 4 (6.8%) | 55 (17.6%) | 0.034 |
Dyslipidemia, n (%) | 57 (22.2%) | 9 (15.3%) | 73 (23.4%) | 0.230 |
Obesity, n (%) | 13 (5.1%) | 6 (10.2%) | 18 (5.8%) | 0.224 |
Family Hx of CAD, n (%) | 47 (18.2%) | 6 (10.2%) | 61 (20.7%) | 0.096 |
Coronary angiographic finding | ||||
 CAS, n (%) | 134 (52.1%)§ | 10 (16.9%) | 121 (38.8%) | 0.001 |
Medication | ||||
 ACEi or ARB, n (%) | 73 (28.5%) | 8 (13.3%) | 84 (26.9%) | 0.033 |
 CCB, n (%) | 79 (30.9%) | 14 (23.3%) | 93 (29.8%) | 0.353 |
 Beta-blocker, n (%) | 36 (14.1%) | 3 (5.0%) | 46 (14.7%) | 0.039 |
 Statins, n (%) | 38 (14.8%) | 2 (3.3%) | 38 (12.2%) | 0.041 |
 Anti-platelet agent, n (%) | 68 (26.6%)§ | 18 (30.0%) | 109 (34.9%) | 0.552 |
Laboratory finding | ||||
 Glucose, mg/dL | 114.0 ± 36.2 | 127.1 ± 130.4 | 107.4 ± 23.9 | 0.347 |
 Total cholesterol, mg/dL | 179.8 ± 42.2 | 190.5 ± 40.1 | 185.8 ± 44.7 | 0.501 |
 HDL, mg/dL | 46.2 ± 30.2§ | 50.8 ± 10.8 | 52.3 ± 14.9 | 0.428 |
 LDL, mg/dL | 122.9 ± 34.0§ | 110.6 ± 33.5 | 112.0 ± 34.1 | 0.580 |
 Triglyceride, mg/dL | 169.0 ± 108.6§ | 126.8 ± 71.2 | 137.6 ± 125.8 | 0.440 |
 hs-CRP, mg/dL | 2.20 ± 4.20 | 1.16 ± 1.32 | 2.59 ± 7.30 | 0.040 |